SLC23A1: A Potential Drug Target for Transport Across Cell Membranes and Associated with Various Diseases

Target Name: SLC23A1

NCBI ID: G9963

SLC23A1

SLC23A1: A Potential Drug Target for Transport Across Cell Membranes and Associated with Various Diseases

SLC23A1 is a member of the solute carrier family 23, which is responsible for transporting a variety of molecules across cell membranes. It is a protein that is expressed in many different tissues and organs, including the brain, heart, and kidneys. SLC23A1 has been identified as a potential drug target or biomarker due to its involvement in the transport of certain molecules that are associated with a variety of diseases, such as diabetes, hypertension, and neurodegenerative disorders.

SLC23A1 is a transmembrane protein that is composed of an intrinsically disordered N-terminus, a transmembrane segment, and an intracellular tail. It has a calculated molecular weight of 42 kDa and a pI of 6.5. SLC23A1 is primarily expressed in the brain and is also found in other organs, including the heart, kidneys, and liver. It is thought to be involved in the transport of a variety of different molecules, including ions, nutrients, and toxins.

One of the reasons why SLC23A1 has been identified as a potential drug target is its involvement in the transport of certain molecules that are associated with a variety of diseases. For example, SLC23A1 has been shown to be involved in the transport of hyperkalemia, which is a condition in which the level of potassium in the body is too high. Hyperkalemia is often associated with a variety of disorders, including heart failure, neurodegenerative diseases, and kidney disease.

SLC23A1 is also involved in the transport of other molecules that are associated with a variety of diseases, including diabetes and hypertension. For example, SLC23A1 has been shown to be involved in the transport of glucose, which is a sugar that is used as an energy source by the body. Hyperglycemia, or high blood sugar, is often associated with a variety of disorders, including diabetes and cardiovascular disease. SLC23A1 has also been shown to be involved in the transport of other molecules, including amino acids, which are important for the structure and function of the body's cells.

In addition to its involvement in the transport of certain molecules, SLC23A1 has also been shown to play a role in the regulation of other processes in the body. For example, SLC23A1 has been shown to be involved in the regulation of ion homeostasis, which is the balance of the number of positive and negative ions in the body. This is important for maintaining the stability of the body's cells and tissues. SLC23A1 has also been shown to be involved in the regulation of the blood-brain barrier, which is the barrier that separates the brain from the rest of the body and helps to protect it from harmful substances.

SLC23A1 has also been shown to play a role in the development and progression of certain diseases. For example, SLC23A1 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It has also been shown to be involved in the development of certain cardiovascular diseases, such as heart failure and hypertension.

Despite its involvement in a variety of important processes in the body, SLC23A1 is not yet well understood. There are currently no approved drugs that are specifically designed to target SLC23A1, and more research is needed to fully understand its role in the body and its potential as a drug target.

Protein Name: Solute Carrier Family 23 Member 1

Functions: Sodium/ascorbate cotransporter. Mediates electrogenic uptake of vitamin C, with a stoichiometry of 2 Na(+) for each ascorbate

The "SLC23A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC23A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets